8-K: Neuraxis Amends Securities Purchase Agreement, Secures $3 Million Investment

Neuraxis, Inc. has amended its securities purchase agreement with Flagstaff International, LLC, securing a $3 million investment through a convertible promissory note.

Summary

• Neuraxis, Inc. amended its Securities Purchase Agreement with Flagstaff International, LLC on February 12, 2024.
• The amendment replaces the original agreement's Article II, detailing the purchase and sale of a convertible promissory note.
• Flagstaff International will purchase a $3 million convertible promissory note, which can be converted into 1,260,504 shares of Series B Preferred Stock.
• The purchase price will be paid in 15 equal monthly installments of $200,000, starting January 10, 2024.
• Neuraxis has the option to issue shares of Series B Preferred Stock in lieu of monthly funding from Flagstaff, at a rate of $200,000 worth of shares per month.
• The proceeds from the note will be used for working capital and general corporate purposes, and cannot be used for dividends, distributions, or payments to officers, directors, or affiliates.
• The closing of the transaction was set for on or before January 10, 2024.
• The agreement also includes amendments to the conditions of closing, requiring a good standing certificate and compliance with existing agreements.

Sentiment

Score: 7

Explanation: The document indicates a positive development for the company, securing a significant investment. However, there are some restrictions on the use of funds and the need for shareholder approval, which temper the overall sentiment.

Positives

• The amendment secures a significant $3 million investment for Neuraxis.
• The flexible structure allows Neuraxis to potentially reduce debt by issuing shares instead of receiving monthly funding.
• The funds are earmarked for working capital, which can support the company's operations and growth.
• The agreement includes a clear timeline for payments and closing.

Negatives

• The company is restricted from using the funds for dividends, distributions, or payments to insiders.
• The company is required to comply with a number of conditions to close the transaction.

Risks

• The company's ability to issue shares in lieu of funding is contingent on stockholder approval and the filing of the Certificate of Designation.
• The company is reliant on Flagstaff International to make the monthly payments.
• There is a risk that the company may not be able to meet the conditions for closing the transaction.

Future Outlook

The company intends to use the proceeds for working capital and general corporate purposes. The company will also seek stockholder approval for the creation of the Series B Preferred Stock.

Industry Context

This type of financing is common for companies seeking growth capital, particularly in the biotech or pharmaceutical sectors. The use of convertible notes allows investors to participate in potential upside while providing the company with immediate funding.

Comparison to Industry Standards

• The use of convertible promissory notes is a fairly standard method for raising capital, especially for companies that may not yet be profitable or have a stable cash flow.
• The 8.5% interest rate on the notes is within the typical range for such instruments, although it can vary based on the company's risk profile and market conditions.
• The conversion price of $2.38 per share is a key factor for investors, as it determines the potential equity stake they will receive upon conversion.
• The 15-month maturity date is a relatively short timeframe, which may indicate that the company expects to achieve certain milestones or raise additional capital within that period.
• The inclusion of registration rights is a standard practice to ensure that investors can eventually sell their shares in the public market.

Stakeholder Impact

• Shareholders will see potential dilution if the convertible notes are converted to equity.
• Employees may benefit from the increased working capital.
• Customers and suppliers may see improved stability and operations due to the funding.
• Creditors may see improved financial health of the company.

Next Steps

• Neuraxis needs to obtain stockholder approval for the creation of the Series B Preferred Stock.
• The company needs to file the Certificate of Designation with the Secretary of State of Delaware.
• Flagstaff International will make monthly payments of $200,000.
• Neuraxis may choose to issue shares in lieu of monthly funding.

Key Dates

Keywords

convertible promissory note, securities purchase agreement, Series B Preferred Stock, Flagstaff International, investment, working capital, capital raise, Neuraxis